Threat of Trump’s pharma tariffs looms again
Pharmaphorum
The Trump administration is said to be preparing to announce tariffs of up to 100% on some pharmaceutical imports.
Merck KGaA acquires JSR chromatography business
Pharmaceutical Technology
Merck KGaA has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Alzheimer’s biotech Korsana to go public via reverse merger
Pharmaphorum
By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer’s.
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets
BioPharma Dive
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.
FDA approves Lilly obesity pill, triggering battle with Novo Nordisk
BioPharma Dive
Foundayo could erase the Wegovy pill s four-month head start as the two drugmakers clash on a debate of efficacy and convenience.
Lilly bags FDA okay for Wegovy pill rival orforglipron
Pharmaphorum
Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill.
Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry
BioSpace
The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.
Ambrosia adds a megaround for obesity drugs
BioPharma Dive
The $100 million Series B round will be used to bring the biotech s oral GLP-1 into early human testing.
FDA approves new high dose Spinraza regimen for SMA
Viridian reports positive results from elegrobart phase 3 trial
PharmaTimes
Company says treatment shows strong efficacy and convenient dosing profile
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Pharmaceutical Technology
Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
BioSpace
Biogen, Eli Lilly, Merck and Novartis spent more than $20 billion to absorb biotechs with promising or approved drugs; the rare disease space notched approvals for therapies from Denali Therapeutics,
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
BioSpace
While peptides are currently the dominant approach to GLP-1 agonism, Ambrosia Biosciences is pursuing a small-molecule approach.
FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries
BioSpace
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile.
IO Shuts Down Following Regulatory Roadblocks
BioSpace
The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma.
EMA seeks input on virtual alternative to animal test
Pharmaphorum
EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.
Novo Sheds 400 at Embattled Manufacturing Site
BioSpace
Follow along as BioSpace tracks job cuts and restructuring initiatives.
FDA, after turbulent year, leaves drugmakers guessing on its direction
BioPharma Dive
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator is as unpredictable as it s ever been.
A ‘hijacked plane’: CDC, under RFK Jr.’s influence, trades science for dogma
BioPharma Dive
A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications for public health.